Results 61 to 70 of about 59,855 (258)

The effect of antipsychotic-induced extrapyramidal disorders on patient’s compliance with schizophrenia (a clinical case)

Бюллетень сибирской медицины, 2022
Extrapyramidal disorders are common adverse events in antipsychotic therapy. However, their diagnosis is difficult due to broad differential diagnosis, and often their specific clinical variant is not recognized, and timely intervention is not performed,
E. G. Rahim, E. G. Kornetova, A. A. Goncharova, A. N. Кornetov, A. V. Semke   +4 more
doaj   +1 more source

Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview

MedComm, Volume 7, Issue 6, June 2026.
The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele, Ajit Manchare, Swapnali Parit, Amol D. Gholap, Krishna Jadhav, Navnath Hatvate, Keshav Raj Paudel, Satish Rojekar   +7 more
wiley   +1 more source

Clinical Studies on 1 Case of Tradive Dyskinesia by Oriental Medical Treatment

Journal of Pharmacopuncture, 2002
Objective : This study was performed to evaluate the treatment of acupuncture therapy including Herbal Acupuncture in Tardive Dyskinesia. Methods & Result : We treated 1 case of Tardive Dyskinesia patient with Acupuncture and herbal Acupuncture, herbal
Chang-Suk, An, Chang-Kil, Yoo, Tae-Hui, Kim, Ki-Rok, Kwon, Sung-Mo, Choi   +4 more
doaj   +1 more source

Electroconvulsive Therapy for Severe Refractory Tardive Dystonia Without Active Depression: A Case Report

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Electroconvulsive therapy produced clinically meaningful improvement in severe refractory tardive dystonia without active depression, including recovery of independent ambulation. However, symptom recurrence after discontinuation highlights the potential need for continuation or maintenance strategies.
Tomohiro Asahi, Yasushi Kawamata, Norio Sugawara, Ryo Maehara, Norio Yasui‐Furukori   +4 more
wiley   +1 more source

Efficacy and safety of 2–4 mg brexpiprazole in the management of schizophrenia: A systematic review and meta‐analysis

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
This graphical summary illustrates the efficacy and safety of brexpiprazole (2–4 mg) in patients with schizophrenia. The meta‐analysis demonstrates significant improvement in clinical outcomes, with reductions in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression ‐ Severity scale (CGI‐S) scores, indicating better symptom ...
Sher Bano, Aashan Ahmad, Abdul Haseeb Mohammed, Ismailova Rushana Nurbekovna, Saja Saad, Noor Fatima, Muhammad Bilal Akbar, Zainab Salahuddin, Sadikun Nabi, Mohammad Mustafa Ababneh, Laiba Ajmal, Sidra Hariss, Hiba Manaf, Farah Saleh, Raouf Khan   +14 more
wiley   +1 more source

Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Modern psychiatric treatment often necessitates polypharmacy, yet combination regimens carry significant risks of metabolic burden and drug–drug interactions. There is growing interest in and clinical acceptance of rational, mechanism‐based drug combinations that are designed around desirable pharmacological properties rather than trial and ...
Avery D. Franzen, John S. Svendsen, Cassidy J. Kline, Susan Q. Shen   +3 more
wiley   +1 more source

Improvement of Tardive Dyskinesias with Olanzapine [PDF]

, 2023
Sara Echater, Bouchra Oneib
openalex   +1 more source

Underprescription of Clozapine: A Narrative Review Regarding ‘Clozaphobia’

Human Psychopharmacology: Clinical and Experimental, Volume 41, Issue 3, May 2026.
ABSTRACT This review aims to examine the appropriateness of the term ‘clozaphobia’ to characterise the obstacles contributing to the underprescription of clozapine (CLZ). English‐language, peer‐reviewed studies addressing clinicians', patients' and/or carers' attitudes toward CLZ were considered eligible for full‐text review.
Rafael Brito Castro, Joaquim J. Ferreira, João Gama‐Marques   +2 more
wiley   +1 more source

VITAMINE E IN THE MANAGEMENT OF DRUG INDUCED TARDIVE DYSKINESIA: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

Journal of Research in Medical Sciences, 2002
Introduction. Expresssion of tardive dyskinesia as one of the side effects of antipsychotic drugs causes various problems in psychotic patients. It is the main cause of patient"s drug incompliance.Vitamine E with it"s antioxidants properties might be an ...
M KAR AHMADI, F RAJAY
doaj  

Tardive dyskinesia in schizophrenia [PDF]

British Journal of Psychiatry, 2013
SummarySarró et al report grey matter deficits associated with tardive dyskinesia in schizophrenia. Much evidence suggests that the intrinsic pathophysiology of schizophrenia contributes to predisposition to tardive dyskinesia. The possibility that antipsychotics might play a causal role in the grey matter deficits cannot be excluded, but the evidence ...
openaire   +2 more sources